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Background: Keratin-producing odontogenic cysts (KPOCs) are a group of cystic lesions that are often aggressive,
with high rates of recurrence and multifocality. KPOCs included orthokeratinised odontogenic cyst (OOC) and
parakeratotic odontogenic cysts, which are now considered true tumours denominated keratocystic odontogenic
tumours (KCOTs). GLUT1 is a protein transporter that is involved in the active uptake of glucose across cell
membranes and that is overexpressed in tumours in close correlation with the proliferation rate and positron
emission tomography (PET) imaging results.
Methods: A series of 58 keratin-producing odontogenic cysts was evaluated histologically and immunohistochemically
in terms of GLUT1 expression. Different data were correlated using the beta regression model in relation to histological
type and immunohistochemical expression of GLUT1, which was quantified using two different morphological methods.
Results: KPOC cases comprised 12 OOCs and 46 KCOTs, the latter corresponding to 6 syndromic and 40 sporadic KCOTs.
GLUT1 expression was very low in OOC cases compared with KCOT cases, with statistical significant differences when
quantification was considered. Different GLUT1 localisation patterns were revealed by immunostaining, with the parabasal
cells showing higher reactivity in KCOTs. However, among KCOTs cases, GLUT1 expression was unable to establish
differences between syndromic and sporadic cases.
Conclusions: GLUT1 expression differentiated between OOC and KCOT cases, with significantly higher expression
in KCOTs, but did not differentiate between syndromic and sporadic KCOT cases. However, given the structural
characteristics of KCOTs, we hypothesised that PET imaging methodology is probably not a useful diagnostic tool
for KCOTs. Further studies of GLUT1 expression and PET examination in KCOT series are needed to confirm this
last hypothesis.
Keywords: Glucose transporter protein, Immunohistochemistry, Keratin-producing odontogenic cyst, Keratocystic
odontogenic tumour, Orthokeratinised odontogenic cyst, Positron emission tomographyBackground
Keratin-producing odontogenic cysts (KPOCs) form a het-
erogeneous group of cystic lesions that are often aggressive
in character, with high rates of recurrence and multifocality
[1], associated to a marked proliferative activity [2, 3]. The
lesional spectrum of KPOCs includes primarily orthokera-
tinised odontogenic cysts (OOC) and odontogenic kerato-
cysts, which, according to WHO guidelines [4] are also* Correspondence: fco.jose.vera@uv.es
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Effective management of these cystic lesions is subject to
frequent discussion [5] and malignant transformation is
possible, albeit very rare [6].
Glucose, as a primary energy source, enters intracellu-
larly by a family of transporters called GLUTs, of which at
least 13 members are now know with cell-specific expres-
sion [7]. Within these families, GLUT1 or erythrocyte glu-
cose transporter is over-expressed in tumours, particularly
in malignant lesions, as glucose is the main energetic
source of these neoplastic growths [8]. This is based onticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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sion tomography (PET) alone or combined with computed
tomography (PET-CT), that used as radiotracer the glu-
cose analogue 18F-fluorodeoxyglucose (18FGD) [9].
In head-and-neck area, GLUT1 was also overexpressed
at particular times in some benign tumours [10, 11], par-
ticularly those with marked proliferative activity [12].
Likewise, in some benign odontogenic tumors with high
recurrence rates, it has been noted that GLUT1 overex-
pression, to the extent that it may be useful for PET or
PET-CT to assess the recurrence of these benign
tumours [13]. However, in our knowledge, GLUT1 ex-
pression has not been investigated in KPOCs with a high
rate of recurrence, which are presently regarded as a
true odontogenic tumours with a high probability of
relapse [1, 4, 5].
In the present study, we aimed to analyse, for the first
time to our knowledge, GLUT1 expression in a series of
KPCOs, to differentiate histological subtypes and evalu-
ate the potential for use of PET in the diagnosis of these
lesions, similar to what has been reported in other be-
nign tumours of the head and neck with high recurrence
rates [13].
Methods
We studied 58 cases of KPOCs that were diagnosed over
a period of 10 years (2005-2015) at the Department of
Pathology of La Fe University Hospital, Valencia, Spain.
Histological material was retrieved from storage. Our
work formed part of a project previously approved by
our Institutional Review Board (Comité Ético de Investi-
gación Clínica -CEIC-) (protocol no. 2013/0045) and the
guidelines outlined in the Declaration of Helsinki, as
revised in Séul -Corea- 2008 were strictly followed. Prior
to performing oral surgery, written informed consent
was obtained in all patients, communicating the partici-
pation of its oral biopsy specimen in this immunohisto-
chemical study. We selected cases using a pathological
diagnosis data base (Pat Win® version 4.1.4). We per-
formed a 10-year retrospective search employing the
search terms “keratocyst”, “primordial cyst”, “keratocys-
tic odontogenic tumour”, “orthokeratinised odontogenic
cyst”, and “keratinized cyst”, understanding the varied
nomenclature [14] used in these lesions.
All original histological sections were reviewed
microscopically by two observers (BVS, FVS), and were
reclassified using the WHO 2005 guidelines (4) and
diagnostic criteria outlined in the OOC [15, 16]. The
clinical, radiological, and surgical data on all patients
were gathered from the medical records using the
Mizar® 2.0 platform with the aid of the viewfinder Luna®
3.0. We noted the following data: age; gender; location
of the lesion (mandibular and/or maxillary); clinical/
radiological follow-up findings, number of recurrences;and any clinical, pathological, or genetic data suggest-
ing a syndromic association. We used the criteria of
Kimonis et al. [17] to diagnose nevoid basocellular car-
cinoma syndrome (NBCCS).
Sections 5 μm in thickness were cut from the original
paraffin-embedded blocks and mounted on poly-Llysine-
coated glass slides prior to immunohistochemical staining.
Epitope retrieval proceeded at 97°C for 20 min in high-pH
EnVision FLEX Target Retrieval solution, followed by
washing for 5 min in EnVision FLEX Wash Buffer. GLUT
1 was immunostained using a concentrated polyclonal
antibody (Master Diagnostica, Granada, Spain), at 1/50
dilution. The incubation time was 20 min and staining
was visualized using the high-pH EnVision FLEX system.
Placental sections and erytrocytes membranes served,
respectively, as external and internal, positive staining
controls and the negative controls were mock-stained
test sections (the primary antibody was replaced by
phosphate-buffered saline –PBS-).
GLUT 1 immunostaining at epithelial level of KPOC
was quantified using the Leica DMD108 digital micros-
copy system (Leica Microsystems©, Wetzlar, Germany)
and two different procedures. First, the thickness (values
from 0 to 100 %) of the epithelium marked by GLUT1
was measured. Second, an immunoreactivity score for
GLUT1 (IRS-GLUT1), based on the IRS described by
Remmele et al. [18], was established. IRS assesses two pa-
rameters: immunostaining intensity (0 = absent; 1 = weak;
2 =moderate; 3 = strong) and percentage of labelled cells
(values from 0 to 4: 0 = 0 %; 1 = 1-25 %; 2 = 25-50 %; 3 =
50-75 %; 4 = 75-100 %). Product of both parameters sup-
plies the IRS (values from 0 to 12). Additionally, location
of immunostaining (basal, suprabasal, intermediate or
superficial) was recorded.
The results obtained were expressed as the mean,
standard deviation (sd), median and interquartile range
for each lesional type. To contrast the differences in the
expression of GLUT1, the percentage thickness of the
epithelium stained and IRS score were compared, using
the beta regression model, rescaling the variables "score"
and “percentage thickness stained” at range [0-1]. Statis-
tical analysis was performed using the statistical software
R, version 3.1.2, considering a P value less than 0.05 as
indicative of statistical significance.
Results
Upon histological review, the 58 KPOCs were classified,
using the WHO criteria, into 46 KCOTs and 12 OOCs.
Of the 46 KCOT cases, 6 were considered to be syn-
dromic KCOT (S-KCOT) because other lesions or ab-
normalities consistent with the presence of NBCCS were
also noted. Table 1 summarises the epidemiological data,
as well as the frequency of recurrences, based on infor-
mation from the clinical and radiological follow-up.
Table 1 Epidemiological and follow-up data
Lesional type N° cases Mean age (years) M/F ratio Follow-up a % Recurrence Location b
Mb - 83,33 %
OOC 12 35,50 ± 12,10 7/5 39,0 ± 26,01 0 % Mx - 16,66 %
Mb - 75,00 %
NS-KCOT 40 45,67 ± 21,20 21/19 29,6 ± 31,04 35 % Mx - 22,50 %
Mb & Mx - 2,50 %
Mb - 33,33 %
S-KCOT 6 23,00 ± 18,07 1/5 112,0 ± 76,10 100 % Mx - 16,33 %
Mb & Mx - 50,00 %
a Clinico-radiological mean follow-up expressed in months
b Mb: mandibular; Mx: maxillar
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S-KCOT (six cases) affected five females and one male,
aged 9–54 years, and the mean patient age at the time of
diagnosis was 23 ± 18.07 years. All patients had recur-
rences; the mean number of recurrences was 3 ± 1.41
over a mean follow-up time of 112 ± 76.1 months.
Lesions occurred in the mandible and maxilla (three
patients), mandible alone (two patients), and maxilla
alone (one patient). The premolar region was the most
frequently affected, followed by the molar and anterior
regions.
Non-syndromic KCOT (NS-KCOT; 40 cases) occurred
in 21 males and 19 females (M/F ratio: 1.10) with a
mean age of 45.67 ± 21.2 years (range, 9–84 years), and
35 % of patients (14 of 40) had recurrences (an average
of 1.4 ± 0.6 relapses) over 29.6 ± 31.04 months of follow-
up. Of all patients, 75 %, 22.5 %, and 2.5 % had lesions
in the mandible, maxilla, or both, respectively. The pre-
molar mandibular region was most frequently affected,
and the anterior region least affected.
OOCs were noted in seven males and five females, and
the mean age at diagnosis was 35.5 ± 12.1 years (range,
19–65 years). Of all patients, 83.5 % had mandibular in-
volvement exclusively, and only two had lesions in the
maxilla. The molar mandibular area, followed by the pre-
molar mandibular region, was the most frequently affected
site. Five of the twelve cysts (41.6 %) were associated with
impacted teeth and were initially clinically and radiologic-
ally misdiagnosed as dentigerous cysts. No OOC patient
had multiple lesions, and no patient had recurrence or de-
veloped of another lesion during a mean follow-up time of
39 ± 26.1 months (range, 9–95 months), confirming a sig-
nificant difference (p = 0.039) compared with OOC against
all KPOCs in relation to recurrence.
After performing immunohistochemistry in our KPOC
series (Figs. 1 and 2), we observed that GLUT1 expression
was low and inconspicuous in OOC, showing only an
weak cytoplasmic and membranous reactivity, that was
distributed, in the basal, parabasal and intermediate layersof cystic epithelium, sometimes with a predominance in
the basal reactivity. In contrast, immunoreactivity was
greater in KCOT, with more pronounced membranous
immunostaining in parabasal than in basal cells. Inter-
mediate cells of KCOT were also labelled but with moder-
ate immunostaining, often somewhat higher than basal
cell. Furthermore, we observed that GLUT1 immuno-
staining was very similar, both in intensity and location, in
S-KCOTand NS-KCOT cases.
Regarding quantification of GLUT1 expression, the
IRS-GLUT1 (score with values ranging from 0 to 12)
numerical results were generally low (Table 2), especially
in OOC cases (mean score: 3.84 ± 2.93) compared with
KCOT cases (mean score: 5.53 ± 2.62 ). Compared both
mean scores, using the beta regression model, a statistical
trend close to significance (p = 0.057) was found, in rela-
tion to the IRS of OOC group, which were lower those in
the KCOT group. Likewise among the KCOT cases, the S-
KCOTcases showed a slightly higher IRS (6.28 ± 2.13) that
the NS-KCOT cases (IRS: 5.37 ± 2.72) and than the IRS
values of both subgroups S-KCOT and NS-KCOT, albeit
with no significant difference ( p = 0.477).
By contrast, in assessing the expression by the epithe-
lial thickness percentage GLUT1+ (Table 2) (Fig. 2), we
found that OOC cases have a smaller thickness (31.46 ±
19.94 %) with GLUT1+ immunostaining than KCOT
cases (56.61 ± 22.34 %), and the difference was statisti-
cally significant (p = 0.002). Thus, the analysis of the
percentage thickness of the epithelium GLUT1+ staining
allowed discrimination of the two KPOC subtypes.
Finally, in S-KCOT subgroup, the percentage thickness
with GLUT1+ immunostaining (66.42 ± 17.96 %) was
higher than that in the sporadic (NS-KCOT) cases
(52.03 ± 22.60 %), albeit with no significant difference
(p = 0.128).
Discussion
In the present study, we have analysed for the first time
to our knowledge, the expression of GLUT1, a protein
transporter involved in the active uptake of glucose
Fig. 1 GLUT1 expression in KCOT and OOC. KCOT (a and b) showing a pronounced GLUT1 immunostaining with a predominantly membranous
pattern (a). Immunoreactivity is especially marked in the parabasal and intermediate epithelium levels (b). Weak GLUT1 immunostaining in OOC (c and d),
with a granular cytoplasmic and also slightly membranous pattern, somewhat more pronounced at basal level (d). (GLUT1, 200x and 400x)
Vera-Sirera et al. BMC Oral Health  (2016) 16:32 Page 4 of 7across cell membranes, in a series of KPOCs, which con-
stitute a heterogeneous group of cystic odontogenic le-
sions, that are often aggressive in character, with high
rates of recurrence and multifocality [1], and are associ-
ated with a marked proliferative activity [2, 3].
GLUT1 expression has an important relationship with
18FGD-PET methodology, a rapidly developing functional-
imaging modality that has shown great promise in the
fields of primary, recurrent and metastatic tumour detec-
tion, as well as in the planning and monitoring of the ther-
apy of various tumours [19].Fig. 2 GLUT1 expression in KCOT and OOC. Panoramic view and details o
(e,f,g and h), displaying the different proportion of the epithelial thickne
an intense labelling, as an internal positive control. (GLUT1, 100, 200x andGLUT1 or erythrocyte glucose transporter is the
best-known member of the GLUTs family of insulin-
independent transporters that are overexpressed in
tumoural lesions [7], especially malignant ones, given
the increased glucose consumption present in tumour
cells needed to provide energy to cell proliferation [8].
GLUT1 expression in different models of tumour
growth has been closely correlated, first, with the rate
of cell proliferation, and second, with the effectiveness
of 18FGD-PET methodology as diagnostic imaging
technique [20], given that, like glucose, 18FDG passesf GLUT1 immunostaining in KCOT (a,b,c and d) and OOC samples
ss with GLUT1 immunostaining. Erythrocytes (asterisks) appears with
400x)
Table 2 GLUT-1 expression in KPOC cases
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subjected to phosphorylation by hexokinase to form
FDG-6-phosphate. FDG-6-phosphate is not metabolised
further, and accumulates in tissues with active glucose
metabolism [21].
Within the lesional spectrum of KPOC, cystic forms of
relatively innocuous character have been identified, such
as the so-called OOC [15, 16]; and also included aggres-
sive forms, classically denominated odontogenic kerato-
cysts [1] and today called KCOT [4]. These latter lesions
show marked proliferative activity [2, 3] and have a high
potential for recurrence [5], to the point of being consid-
ered true odontogenic tumour growth [4].
In our results we verified that the OOC present in the
basal, parabasal and intermediate layers a very limited ex-
pression of GLUT1. Comparatively KCOT cases show a
high reactivity, focused mainly on the layer of parabasal
cells. Additionally, the expression levels of GLUT1 quanti-
fied in OOC and KCOT showed a statistically significant
difference (or were close to statistical significance) accord-
ing to the thickness of the cystic epithelium marked by
GLUT1 or IRS-GLUT1, respectively. However, in our
study, GLUT1 expression not discriminate between syn-
dromic and sporadic cases of KCOT.
In tumours, GLUT1 expression is well correlated with
cellular proliferative rates given the active glucose
metabolism of highly proliferating tumours [21]. This re-
lationship was confirmed in our study by the clear differ-
ences in the expression of GLUT in OOC and KCOT.
Our results appears to be in agreement with those of
other studies that reported obvious differences in the
proliferation rates of both cystic odontogenic lesions,
using various proliferative immunohistochemical markers,
such as Ki 67 [2] or cyclin D1 [2, 3]. GLUT1 expression
was established in our KCOT cases, with higher inten-
sity, particularly at the parabasal cells level, and these
data reinforced the role of the parabasal cells as protag-
onists elements in the tumour growth of KCOT [2, 3].
Considering that the type of treatment performed is
known to have a remarkable influence in recurrence
rates of KCOT [5], it should be noted that, given the
retrospective character of our study, with various and
non-homogeneous treatments, it is not possible toestablish with certainty the relationship between
GLUT1 expression and lesional recurrence.
Another aspect to consider is the relationship between
the expression of GLUT1 and the efficacy of tumour de-
tection by PET or combined PET-CT. Several immunohis-
tochemical studies have demonstrated overexpression of
GLUT1 in human malignant tumours and a correlation
between GLUT1 expression and neoplastic progression
[21]. Additionally, the overexpression of GLUT1 has been
reported to be closely related to 18FGD uptake on PET,
because 18FGD is also taken up via intracellular transport
by GLUT1 [21–25].
Possible uses and applications of PET are paradoxically
not limited to malignant tumours; thus, in the head-
and-neck area, it has been noted that some benign
tumours [26], such as pleomorphic adenoma [10], myofi-
broma [12] and ceruminous adenoma [11], demonstrate
positivity by PET. These benign lesions are often in-
cluded in the list of possible errors and pitfalls in the
evaluation of head-and-neck cancers using PET but this
correct knowledge can provide useful diagnostic infor-
mation in an adequate clinical context [26].
Within odontogenic tumours, a previous study [13]
showed four cases of ameloblastoma, a benign tumor with
a high recurrence rate, with reactivity against GLUT1 and
positivity in PET examination, postulating that PET-TAC
can be useful in the imaging diagnosis of recurrences in
ameloblastoma. In this report [13], GLUT1 immunostain-
ing was not quantified, so it is not possible to compare
our results in KCOT with those reported in ameloblasto-
mas. On other hand, there is no published study regarding
the use of PET-CT in the diagnosis or follow-up of KCOT,
and in our series of KPOC, no case underwent PET or
PET-CT examination.
However, despite this latter limitation, several points
suggest that PET methodology is not a useful diagnostic
tool in the case of KCOT. In first place, the mean IRS-
GLUT1 found in our study was low (5.53 ± 2.62) on a
possible maximum punctuation of 12, and a second as-
pect very important to consider is the tumour structure.
Thus, KCOT is a cystic tumoural lesion where GLUT1
reactivity is limited to the epithelial lining. Otsuru et al.
[13] reported a case of unicystic ameloblastoma and
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blastoma showed lower reactivity to GLUT1 and lower
18FDG uptake compared with the solid tumour types
[13]. This finding suggests that the effectiveness of
18FGD-PET is linked, regardless of the reactivity of
GLUT1, to the volume of the tumoural mass [27]. Add-
itionally, the hypothesis that PET-CT methodology is
probably not useful in the case of KCOT, is established
because the cellular uptake of 18FGD by KCOT did not
reach levels sufficient to cause an adequate SUVmax
(maximum standardised value). Further studies, analys-
ing GLUT1 expression and PET in KCOT series, are ne-
cessary, in our opinion, to determine whether analysis of
GLUT1 expression in ameloblastoma is applicable to
KCOT and whether 18FGD-PET is a useful tool in the
diagnosis of KCOT recurrence.Conclusions
GLUT1 expression differentiated between OOC and KCOT
cases, with significantly higher expression in KCOTs, but
did not differentiate between syndromic and sporadic
KCOT cases. However, given the structural characteristics
of KCOTs, we hypothesised that PET imaging methodology
is probably not a useful diagnostic tool for KCOTs. Further
studies of GLUT1 expression and PET examination in
KCOT series are needed to confirm this last hypothesis.Abbreviations
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